| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.02 |
| mRNA | MP470 | GDSC1000 | pan-cancer | AAC | -0.087 | 0.02 |
| mRNA | MS-275 | CTRPv2 | pan-cancer | AAC | 0.076 | 0.03 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.081 | 0.03 |
| mRNA | brivanib | CTRPv2 | pan-cancer | AAC | -0.083 | 0.03 |
| mRNA | CAL-101 | GDSC1000 | pan-cancer | AAC | 0.08 | 0.03 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.073 | 0.03 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | -0.07 | 0.03 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | -0.088 | 0.03 |
| mRNA | Zebularine | CTRPv2 | pan-cancer | AAC | -0.079 | 0.03 |